FDA, EMA Recommend No New Patients Start Lilly Sarcoma Drug After Trial Flops.

Lilly announced last week that the Phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in the Phase II study that led to its accelerated approval.

By ALARIC DEARMENT // Post a comment / Jan 27, 2019 .

... The news is a blow to Lilly, which has sought to diversify its portfolio and drug development efforts into cancers, particularly with the acquisition earlier this month, during the J.P. Morgan Healthcare Conference in San Francisco, of Loxo Oncology for $8 billion. ...